Dexmedetomidine Versus Dexamethasone as Adjuvants to Bupivacaine in Ultrasound-Guided Sphenopalatine Ganglion Block for Functional Endoscopic Sinus Surgery
Key facts
- Who runs it
- Sohag University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 60 people, planned
- Started
- Nov 2026
- Expected to end
- May 2027
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Bupivacaine & normal saline
- Dexmedetomidine & Bupivacaine.
- Dexamethasone & Bupivacaine.
- Record updated
- 10 November 2026
Who can take part
- Age
- 18 years to 60 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Age 18-60 years
- Elective FESS under general anesthesia
- ASA Physical Status I-II
Who cannot take part
- Allergy to local anesthetics
- Coagulopathy or use of anticoagulants
- Anatomical nasal deformities obstructing access
- Patient refusal
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This prospective, randomized, double-blind, controlled trial will compare the efficacy and safety of dexmedetomidine versus dexamethasone as adjuvants to bupivacaine in ultrasound-guided bilateral sphenopalatine ganglion block for adult patients (18-60 years, ASA I-II) undergoing elective functional endoscopic sinus surgery (FESS) under general anesthesia. Participants will be randomly allocated in a 1:1:1 ratio to receive bupivacaine alone, bupivacaine plus dexmedetomidine, or bupivacaine plus dexamethasone. The study will assess postoperative pain scores, duration of analgesia, total analgesic consumption, and intraoperative hemodynamic parameters, in addition to adverse effects.
The 3 groups in the trial
- Group A: BupivacaineExisting treatment, for comparison
Patients will receive ultrasound-guided bilateral sphenopalatine ganglion block with 8 mL of bupivacaine 0.5% plus 2 mL of normal saline, giving a total volume of 10 mL (5 mL per side), after induction of general anesthesia.
Treatment: Bupivacaine & normal saline
- Group B: Bupivacaine + DexmedetomidineTreatment being tested
Patients will receive ultrasound-guided bilateral sphenopalatine ganglion block with 8 mL of bupivacaine 0.5% plus dexmedetomidine 1 µg/kg diluted with normal saline to 2 mL, giving a total volume of 10 mL (5 mL per side), after induction of general anesthesia.
Treatment: Dexmedetomidine & Bupivacaine.
- Group C: Bupivacaine + DexamethasoneTreatment being tested
Patients will receive ultrasound-guided bilateral sphenopalatine ganglion block with 8 mL of bupivacaine 0.5% plus dexamethasone 8 mg (2 mL), giving a total volume of 10 mL (5 mL per side), after induction of general anesthesia.
Treatment: Dexamethasone & Bupivacaine.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Dexmedetomidine Versus Dexamethasone as Adjuvants to Bupivacaine in Ultrasound-Guided Sphenopalatine Ganglion Block in Patients Undergoing Functional Endoscopic Sinus Surgery
- Criteria questions
- Built from NCT07911202, who can take part
- Record updated
- 10 November 2026